Virus-like Particles
A Virus-Like Particle (VLP) is a biological nanoparticle which consists of the protective protein shell of a virus. VLPs are a specific viral subunit that mimics the overall structure of virus particles without the infectious genetic material. VLPs don't contain the viral genetic material rendering them non-infectious and relatively safe for use in various applications, including vaccine development and gene therapy. antibodies-online offers a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios to flexibly meet customer needs. Discover our portfolio down below.
Expression of VLPs
VLPs are derived from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations.
Application of VLPs in Production of Therapeutic Agents and Vaccines
VLPs are highly immunogenic due to high density display of epitopes, the capacity to present multiple proteins to the immune system and their size (typically around 40 nm, influenza VLP however 80–120 nm) which seems to be the optimal for uptake by dendritic cells. Therefore VLPs can serve as effective vaccines. VLPs are particularly beneficial for immunizing against antigens that are present in low abundance or have weak immunogenicity. As they are unable to replicate, they offer a safer alternative to attenuated viruses. Additionally, they enable the soluble expression of multi-transmembrane proteins in their natural configuration.
Spotlight: VLPs for Vaccine Development
The human papillomavirus (HPV) is a DNA virus from the papillomavirus family. Many HPV types are carcinogenic. Nearly all cervical cancer is due to HPV, and two strains – HPV16 and HPV18 – account for 70% of all cases. HPV6 and HPV11 are common causes of genital warts and laryngeal papillomatosis.
HPV envelope proteins are formed by two structural proteins (L1 and L2). L1 makes up about 80 % of the total viral proteins and can assemble spontaneously in vitro with or without L2 to form virus-like particles. This is why HPV VLPs, self-assembled after high level expression of the papillomavirus L1 virion capsid protein in non-mammalian cells, are attractive candidates for a subunit vaccine to prevent genital HPV infection and the subsequent development of cervical cancer. antibodies-online is your reliable partner in vaccine development. Browse our selection of VLPs against key surface targets of HPV or Hepatitis B Virus (HBV).
Moreover, VLPs are a promising option for delivering genes or other therapeutic agents. They are suitable for packaging and targeting drugs (drug delivery), as they can transport therapeutic agents intravenously in high concentrations, with few side effects and in a targeted manner. In vitro studies have demonstrated their effectiveness in selectively targeting cancer cells. Researchers believe that VLPs may accumulate in tumor sites due to the enhanced permeability and retention effect, making them a valuable tool for drug delivery and tumor imaging.
Advantages of VLPs
See all advantages of VLPs at one glance and discover our portfolio down below. antibodies-online offers a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios to flexibly meet customer needs.
- Mammalian cell expression system expression, closer to the real structure and conformation
- Strong immunogenicity
- Biotinylation can be introduced at specific sites
- Proven biological activity
- Design different VLP frameworks for different antigens
Recommended next Filters:
70 results :
